checkAd

     197  0 Kommentare Novozymes delivers resilient full-year results despite the COVID-19 pandemic and is confident about getting back to growth in 2021

    Novozymes delivered flat organic sales growth in the 2020 financial year and an EBIT margin of 26.1%. In 2021 the company expects
    2-6% organic growth supported by innovation, stronger commercial presence, and gradual industry recovery. EBIT margin is expected at a solid 25-26%.

    COPENHAGEN, Denmark – February 2, 2021. In the fourth quarter of the 2020 financial year, Novozymes’ organic sales growth was -3% with reported sales in DKK of -8%. Full-year organic sales growth was 0% with reported sales in DKK down by 3% and an EBIT margin of 26.1%. Full-year ROIC including goodwill was 18.9%.

    “We deliver flat organic sales growth and an EBIT margin of 26% in a year unlike any other in recent history. Our advances through 2020 are a testament to the Novozymes purpose, culture, and well-diversified business model. I’m extremely proud of the work teams across the entire organization have done under these very difficult circumstances. We have managed to make progress and deliver resilient performance despite the pandemic,” says Ester Baiget, President & CEO and continues:

    “Despite the prevailing uncertainties, I’m confident that we will get back to growth in 2021. Growth will be supported by a more streamlined organization, a stronger commercial presence, innovation, and a gradual recovery in the industries negatively impacted by the COVID-19 pandemic. Our global manufacturing sites are fully operational in terms of production and supply chain, and the company continues to fully meet demand.”

    For the full year, organic growth rates by business area were 5% (Q4: 0%) in Household Care, 1% (Q4: -4%) in Food, Beverages & Human Health, -9% (Q4: -4%) in Bioenergy, -1% (Q4: -4%) in Grain & Tech Processing, and 1% (Q4: -6%) in Agriculture, Animal Health & Nutrition.

    Household Care delivered solid organic sales growth driven by the rollout of the Freshness platform, strong market penetration in emerging markets, and changes to consumer behavior induced by COVID-19. Food, Beverages & Human Health organic sales were up slightly as food and human health grew while beverages declined due to COVID-19 effects.

    Organic sales declined in Bioenergy and Grain & Tech Processing as COVID-19 impacted ethanol and textile production. In Agriculture, Animal Health & Nutrition, organic sales grew slightly supported by the rollout of Balancius, stronger inoculant sales in BioAg as well as a one-off.

    For the full year, organic growth rates by geography were 3% (Q4: -1%) in Europe, Middle East & Africa, -4% (Q4: -5) in North America, -1% (Q4: -3) in Asia Pacific, and 6% (Q4: -3) in Latin America.

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Novozymes delivers resilient full-year results despite the COVID-19 pandemic and is confident about getting back to growth in 2021 Novozymes delivered flat organic sales growth in the 2020 financial year and an EBIT margin of 26.1%. In 2021 the company expects 2-6% organic growth supported by innovation, stronger commercial presence, and gradual industry recovery. EBIT margin …